Copenhagen – November 03, 2026 -- Cambiotics ApS has enrolled the first participant in its first human clinical trial, testing whether its probiotic strain 46-SL1 changes serum PFAS concentrations in 70 firefighters with prior occupational exposure.
NEW YORK – November 02, 2026 -- Nuvation Bio (NYSE: NUVB) will present four posters on safusidenib, its investigational mutant IDH1 inhibitor, at the Society for Neuro-Oncology (SNO) Annual Meeting in Philadelphia on November 12-15, 2026. One poster carries updated long-term Phase 2 J201 results that go beyond the topline data the company announced in July 2026.
Shanghai – October 31, 2026 -- Shanghai Zhimeng Biopharma has completed enrollment of 255 patients in the pivotal Phase 2/3 trial of CB03-154 for amyotrophic lateral sclerosis (ALS), moving the potassium channel opener toward topline data and a possible new drug application in China.
Stockholm – October 30, 2026 -- Eisai will present five years of Clarity AD data on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026, according to its partner BioArctic AB (Nasdaq Stockholm: BIOA B). The dataset spans the core and long-term extension phases and is one of the longest follow-up sets reported to date for an approved anti-amyloid Alzheimer's therapy.
SHANGHAI – October 30, 2026 -- Phrontline Biopharma reported partial responses in six of eight response-evaluable urothelial carcinoma patients (75%) treated with its bispecific antibody-drug conjugate (ADC) TJ101, and has dosed the first patient in a Phase Ib trial.
San Diego – October 27, 2026 -- Atrium Therapeutics (Nasdaq: RNA) has dosed the first patient in Corventis, a Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome, and expects initial proof-of-concept data in the second half of 2027.
Global – October 27, 2026 -- Solid Biosciences has dosed the first participant in FALCON, a Phase 1b trial of SGT-212, its investigational gene therapy for Friedreich's ataxia (FA), and expects to release an initial data update in the second half of 2026, subject to patient enrollment.
Boston – October 19, 2026 -- Servier has dosed the first patients in EMBLEM-1, the pivotal Phase 2 cohort of its Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in aggressive adenoid cystic carcinoma (ACC), a cancer with no FDA-approved systemic treatment.
Emi-Le is an investigational antibody drug conjugate (ADC) directed against B7-H4. The cohort is enrolling under trial identifier NCT05377996.
Sydney – October 12, 2026 -- The Safety Review Committee (SRC) for Racura Oncology's HARNESS-1 trial has cleared lead drug RC220 to escalate to 100 mg/m2, after finding no dose-limiting toxicities in either Cohort 1 patient. The Phase 1a/b study combines RC220 with osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC).
Orange County, Calif. – October 07, 2026 -- The Institute for Molecular Medicine (IMM) and Nuravax have dosed the first four participants in TAURUS-1980, a Phase 1 trial testing AV-1980R, described as the world's first active immunotherapy targeting pathological tau protein linked to Alzheimer's disease.
